Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Sells $774,228.09 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $38.01 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a fifty day moving average price of $34.86 and a 200 day moving average price of $35.11. The stock has a market cap of $2.17 billion, a P/E ratio of 18.01, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HRMY. Cantor Fitzgerald lifted their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research report on Thursday, January 16th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 13th. Mizuho boosted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Finally, Oppenheimer reissued an “outperform” rating and issued a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $55.00.

Institutional Investors Weigh In On Harmony Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its stake in Harmony Biosciences by 19.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock valued at $1,852,000 after buying an additional 10,167 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after purchasing an additional 112,197 shares during the last quarter. Hsbc Holdings PLC increased its position in shares of Harmony Biosciences by 208.1% during the 2nd quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock worth $731,000 after purchasing an additional 16,076 shares in the last quarter. Profund Advisors LLC lifted its holdings in Harmony Biosciences by 11.1% during the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock valued at $228,000 after purchasing an additional 758 shares during the last quarter. Finally, Public Sector Pension Investment Board boosted its position in Harmony Biosciences by 2.9% in the second quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock valued at $2,113,000 after buying an additional 1,955 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.